🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Crohn's Disease
Clinical trial register · Poland

Crohn's Disease Trials in Poland, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2681 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:47 UTC
2681
Studies in scope
all four open statuses
1400
Recruiting now
open to new participants
514
Lead sponsors
across recruiting studies
Top sites
Warsaw 21 Krakow 11 Lublin 10 Bydgoszcz 10 Rzeszów 10
Narrow the registerReset
Recruitment status
Phase
Site location
Warsaw21 Krakow11 Lublin10 Bydgoszcz10 Rzeszów10
All 31 locations
Target enrolment
to

Crohn's Disease trials in Poland

27 of 2681 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944Crohn's Disease
Sanofi
Phase 3
751
Bydgoszcz, Kłodzko, Lublin, Staszów, Szczecin, Warsaw
2026-01-22
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
Takeda
Phase 3
70
Rzeszów, Warsaw, Zabrze
2025-10-27
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lodz, Lublin, Nowy Targ
2025-10-01
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
Eli Lilly and Company
Phase 3
290
Lublin, Opole, Piotrkow Trybunalski, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw
2025-06-26
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
Sanofi
Phase 2
99
Wroclaw, Krakow, Lublin, Sopot, Warsaw
2025-06-03
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615Crohn's Disease, Ulcerative Colitis
Takeda
Phase 2
192
Torun, Lublin, Szczecin, Warsaw
2025-05-28
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289Ulcerative Colitis, Crohn's Disease
Takeda
Phase 3
70
Warsaw, Rzeszów, Zabrze
2025-01-22
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
Takeda
Phase 3
396
Lodz, Poznan, Tychy, Warsaw
2025-01-02
Active, closed
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
NCT06681324Crohn's Disease
AstraZeneca
Phase 2
24
Warsaw
2024-12-11
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631Crohn's Disease
Sanofi
Phase 2
260
Torun, Lublin, Warsaw, Sopot
2024-12-10
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
AbbVie
Phase 2
590
Bydgoszcz, Torun, Krakow, Warsaw, Sopot, Tychy, Kielce
2024-09-04
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Bydgoszcz, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Kłodzko, Opole
2024-07-18
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Poznan, Bydgoszcz, Torun, Krakow, Nowy Targ, Oświęcim, Jelenia Góra, Wroclaw
2024-06-05
Active, closed
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935Crohn's Disease
Janssen-Cilag Ltd.
Phase 3
120
Bydgoszcz, Rzeszów, Torun, Warsaw, Wroclaw, Zamość
2024-04-17
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
Janssen Research & Development, LLC
Phase 3
120
Rzeszów, Warsaw
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
Eli Lilly and Company
Phase 3
90
Rzeszów, Warsaw
2024-03-13
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461Crohn's Disease
Takeda
Phase 2
268
Torun, Wroclaw, Warsaw, Szczecin, Bydgoszcz, Lodz, Lublin, Poznan
2024-03-05
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567Ulcerative Colitis, Crohn's Disease
Takeda
Phase 3
240
Krakow, Wroclaw, Warsaw, Rzeszów, Gdansk, Katowice, Szczecin, Lodz
2023-05-16
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Bydgoszcz, Krakow, Lodz, Lublin, Olsztyn, Poznan, Rzeszów, Sopot
2022-07-22
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Eli Lilly and Company
Phase 3
150
Rzeszów, Szczecin, Warsaw, Wroclaw
2021-05-26
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
Eli Lilly and Company
Phase 3
996
Poznan, Bydgoszcz, Krakow, Wadowice, Swidnica, Wroclaw, Lublin, Zamość
2020-06-22
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
Janssen Research & Development, LLC
Phase 2/3
1,409
Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Jelenia Góra, Katowice, Krakow
2018-04-13
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
AbbVie
Phase 3
1,336
Poznan, Torun, Wroclaw, Lublin, Warsaw, Rzeszów, Chojnice, Tychy
2018-04-09
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-poland/condition/crohn-s-disease

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,681 studies in total at the last sync on 26 Sep 2026, 19:47 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies listing the condition Crohn's Disease.

How many Crohn's Disease trials are recruiting in Poland?

18 of the 27 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:47 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Crohn's Disease), 27 studies
PhaseStudiesRecruitingShare
Phase 3181366.7%
Phase 28529.6%
Phase 2/3103.7%

Most active sponsors

Lead sponsors with the most studies (Crohn's Disease)
Lead sponsorStudiesRecruiting
AbbVie63
Takeda66
Eli Lilly and Company43
Sanofi43
Janssen Research & Development, LLC31
AstraZeneca10
Janssen-Cilag Ltd.10
Merck Sharp & Dohme LLC11
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.